Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Archive
Global health
Authors
About
Help
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Archive
Global health
Authors
About
Help
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 14, Issue 6
Intravenous immunoglobulin as a therapeutic option for patients with worsening COVID-19 under rituximab
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
Case report
Intravenous immunoglobulin as a therapeutic option for patients with worsening COVID-19 under rituximab
Online download statistics by month:
Online download statistics by month: June 2021 to July 2022
Abstract
Full
Pdf
Jun 2021
154
155
45
Jul 2021
401
397
122
Aug 2021
80
80
31
Sep 2021
107
105
24
Oct 2021
126
117
39
Nov 2021
90
89
70
Dec 2021
125
120
34
Jan 2022
96
101
21
Feb 2022
69
68
18
Mar 2022
71
73
30
Apr 2022
40
40
11
May 2022
51
53
16
Jun 2022
44
44
11
Jul 2022
2
1
2
Total
1456
1443
474
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF